2020 Article HIV Treatment and Prevention Agents 
IDStewardship
JUNE 19, 2025
AI-Generated Summary This article by infectious diseases pharmacist Aneeka Chavda outlines five key considerations for pharmacists in the treatment of Mycobacterium tuberculosis (TB), particularly drug-sensitive cases. The piece advocates for therapeutic drug monitoring (TDM) in specific high-risk groups to personalize treatment.
Pharmacy Times
JULY 25, 2025
Because of their ability to cover a wide array of bacteria, low adverse effect profile, and oral availability, cephalosporins are commonly used in the treatment of outpatient infections. Both agents have high bioavailability, achieve high urinary concentrations, are available as suspensions, and can be used in infants.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JULY 18, 2025
Image credit: OM | stock.adobe.com Why Proper Disposal Matters Disposing of medications appropriately helps prevent environmental contamination of water and soil. Pharmacists should recommend proper disposal guidance and explain the possible consequences of improper disposal. Insani WN, Qonita NA, Jannah SS, et al. 2020;6(7):e04551.
Pharmacy Times
JULY 19, 2025
Malesker, PharmD, FCCP, FCCM, FASHP, BCPS +1 More Hypertension is widespread and linked to serious health risks, but new treatments for resistant cases target new mechanisms of action. 16 At 12 weeks of treatment, placebo-subtracted reductions in sBP were -11.7 Jansen, PharmD Candidate , Mark A. The 50 mg dose achieved a 7.9
Pharmacy Times
AUGUST 2, 2025
These technologies prevent the risk of both hypo- and hyperglycemic episodes, facilitating safer fasting. Additionally, providers should tailor dietary, hydration, and medication recommendations to post-MBS patients to reduce and prevent complications. Nieto, BS, PharmD Candidate Amy C.
Drug Topics
JULY 30, 2025
Prescription cascades refer to a medication being prescribed to prevent or treat an adverse drug reaction to another medication. Further, it would be potentially inappropriate if there are more suitable treatment alternatives available, such as switching the drug causing the adverse drug reaction.
Pharmacy Times
JULY 8, 2025
Further research is needed on the clinical impact, treatment longevity, and cost implications of biosimilar use in pediatric IBD. 2 Tumor necrosis factor alpha inhibitors (anti-TNFs) have become both first- and second-line therapies for the treatment of pediatric patients with Crohn disease and ulcerative colitis. years (IQR: 8.3–16.2
Expert insights. Personalized for you.
Let's personalize your content